13F filer · CIK 1637946
General Catalyst Group Management, LLC
CAMBRIDGE, MA · filing since Q4 2017 · last filing Aug 17, 2026
Reported value
$188.5M
+$5.0M vs prior
Positions
14
New / sold out
4 / 2
Added / reduced
3 / 1
Turnover
32.7%
buys $60.9M · sells $83.3M
Top-10 weight
99.0%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Parabilis Medicines, Inc. | +1,600,937 | – | +$43.8M |
| New | Odyssey Therapeutics, Inc. | +810,272 | – | +$15.2M |
| New | Doordash Inc. | +2,850 | – | +$525.9K |
| New | Carvana Co | +6,465 | – | +$425.5K |
| Added | Meta Platforms Inc. | +662 | +100.6% | +$372.9K |
| Added | Coupang Inc. | +18,000 | +49.1% | +$312.7K |
| Added | Amazon.com Inc. | +1,300 | +50.3% | +$309.8K |
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | SAMSARA INC | -2,000,000 | -100.0% | $-63.4M |
| Sold out | GITLAB INC | -921,405 | -100.0% | $-19.9M |
| Reduced | Fractyl Health, Inc. | -7 | -0.0% | $-6 |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | ArriVent BioPharma, Inc.COM | 1,494,786 | $51.9M | 27.55% |
| 2 | Parabilis Medicines, Inc.COM | 1,600,937 | $43.8M | 23.24% |
| 3 | Maplebear, Inc.COM | 710,711 | $33.7M | 17.85% |
| 4 | Maze Therapeutics, Inc.COM | 1,035,910 | $30.9M | 16.40% |
| 5 | Odyssey Therapeutics, Inc.COMMON STOCK | 810,272 | $15.2M | 8.04% |
| 6 | Eikon Therapeutics, Inc.COM | 305,233 | $4.0M | 2.11% |
| 7 | Fractyl Health, Inc.COM | 4,884,186 | $3.9M | 2.06% |
| 8 | Ethos Technologies, Inc.CL A | 74,179 | $1.3M | 0.71% |
| 9 | Coupang Inc.CL A | 54,677 | $949.7K | 0.50% |
| 10 | Amazon.com Inc.COM | 3,882 | $925.2K | 0.49% |
4 more rows. Subscribe for $29/month to see every row, download the data and use the API.